Welcome to Aitua
Aitua’s business is the commercialisation of Intellectual Property (IP) in the life science sector, creating value for its shareholders and partners. It actively designs, nurtures and grows companies, building them around novel and defensible IP with products that address a significant market need. Aitua drives early commercial activity and ensures management and shareholder interests are aligned to achieve an early exit. Companies are focused to achieve exits either through IPO or trade sale.
Aitua is located at the heart of the Cambridge biotechnology cluster giving it unique access to Cambridge ideas, innovation and IP. It leverages the entrepreneurial environmental and professional infrastructure to create successful spin-out companies.
The Aitua team have exceptional track records and proven ability to identify market needs. They have extensive expertise in the pharmaceutical industry from discovery and development to market launch. This is combined with a demonstrated capability in making good seed investments and a successful past performance in venture capital.
Working with IP development partners throughout the UK, Aitua has a broad overview of emerging IP which can either be drawn together to create new investment opportunities or licensed to a Portfolio Company to create synergy.
Aitua has an exclusive 10-year pipeline agreement with the Babraham Institute. For further information please click on Partners.
Latest News:
13 June 2008
Aitua Chief Executive Catherine Beech named in Birthday Honours
6 February 2008
Aitua Ltd Portfolio Company enters into agreement with European medical device company, Vygon
13 December 2007
Aitua Ltd Portfolio Company Innova Establishes Worldwide Distributor Network
6 December 2007
Probe Scientific strengthens Board with new appointment
13 November 2007
18 October 2007
BioIndustry Association launches Fledgling Club for early stage bioscience companies
4 October 2007
Aitua invests in ViraBiotech’s instant flu protection